Swiss Group for Clinical Cancer Research
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 1965-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.sakk.ch/
Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 229
- Registration Number
- NCT01926964
- Locations
- 🇨🇭
Spitalzentrum Biel, Biel, Switzerland
🇨🇭Kantonsspital Frauenfeld / Brustzentrum Thurgau, Frauenfeld, Switzerland
🇨🇭Universitaetsspital-Basel, Basel, Switzerland
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 208
- Registration Number
- NCT01835236
- Locations
- 🇨🇭
Hirslanden Klinik Aarau, Aarau, Switzerland
🇨🇭Kantonspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Baden, Baden, Switzerland
Cetuximab for Elderly Patients With mCRC
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 24
- Registration Number
- NCT01718808
- Locations
- 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭Inselspital, Bern, Bern, Switzerland
🇨🇭Spitalzentrum Biel, Biel, Switzerland
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 47
- Registration Number
- NCT01707966
- Locations
- 🇨🇭
Kantonspital Aarau, Aarau, Switzerland
🇨🇭Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭Universitaetsspital Basel, Basel, Switzerland
Therapy De-escalation in Seminoma Stage IIA/B
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 120
- Registration Number
- NCT01593241
- Locations
- 🇩🇪
Berlin Universitätsklinik Charité, Berlin, Germany
🇩🇪Hamburg Universitätsklinikum - Eppendorf, Hamburg, Germany
🇩🇪Aachen Universitätsklinik, Aachen, Germany
Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 33
- Registration Number
- NCT01555281
- Locations
- 🇨🇭
Kantonsspital Olten, Olten, Switzerland
🇨🇭UniversitätsSpital Zürich, Zürich, Switzerland
🇮🇹Istituto Europeo di Oncologia IEO, Milano, Italy
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma
- First Posted Date
- 2011-03-03
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 154
- Registration Number
- NCT01307605
- Locations
- 🇸🇪
University Hospital of Linkoping, Linkoping, Sweden
🇸🇪Karolinska University Hospital - Huddinge, Stockholm, Sweden
🇸🇪Sunderbyn Hospital, Lulea, Sweden
Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery
- Conditions
- Prostate Cancer
- Interventions
- Radiation: radiation therapy
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 350
- Registration Number
- NCT01272050
- Locations
- 🇧🇪
Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium
🇧🇪Ghent University Hospital, Ghent, Belgium
🇩🇪University Hospital and Medical Faculty Technical University of Dresden, Dresden, Germany
Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 44
- Registration Number
- NCT01243385
- Locations
- 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭Kantonsspital Luzern, Luzerne, Switzerland
🇨🇭Kantonsspital - St. Gallen, St. Gallen, Switzerland
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
- Conditions
- Mature T-cell and Nk-cell NeoplasmsLymphomaMultiple Myeloma and Plasma Cell NeoplasmLeukemia
- Interventions
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 18
- Registration Number
- NCT01164709
- Locations
- 🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland
🇨🇭Inselspital Bern, Bern, Switzerland
🇨🇭Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland